TRIL

XT.COM Lists TRI in Its Main Zone

Retrieved on: 
Thursday, November 24, 2022
Ethereum, Interface, Decentralized finance, Trillando la fina, USDT, XT, UTC, APY, TRIL, Ecosystem, TRI, Cryptocurrency

TRI is an ERC-20 token deployed on the layer-1 Ethereum blockchain with a total supply of 50 billion tokens.

Key Points: 
  • TRI is an ERC-20 token deployed on the layer-1 Ethereum blockchain with a total supply of 50 billion tokens.
  • The TRI token contract has a built-in "buyback" function where it helps manage the tokens in circulation ensuring it stays deflationary for sustainable price growth.
  • Both long and short term staking options are available for the TRI token generating a fixed weekly reward in the form of Trillant's stablecoin (TRIL).
  • Deposit, trading, and withdrawal options will be available live and colored for both TRI and XT holders.

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

Retrieved on: 
Friday, June 17, 2022
Time, Lymphatic system, Cancer, Securities Exchange Act of 1934, Administration, COVID-19, TSX, TRIL, SEDAR, Company, Audit committee, Phenotype, Biotechnology, Forward-looking statement, Research, Clinical trial, Pfizer, Travel, Corporation, CFO, NASDAQ, Acquisition, Neuroscience, Neoplasm, DMAC, Therapy, Department of Finance and Administration, Regulation, Management, Pharmaceutical industry, Oncolytics Biotech, Trillium, Finance

SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM.

Key Points: 
  • For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at www.sedar.com .
  • Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
  • Mr. Parsons is a life sciences industry veteran with over two decades of executive experience.
  • Prior to his time at Trillium, Mr. Parsons provided financial consulting services as the President of Empar Management.

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

Retrieved on: 
Friday, June 17, 2022
Time, Lymphatic system, Cancer, Securities Exchange Act of 1934, Administration, COVID-19, TSX, TRIL, SEDAR, Company, Audit committee, Phenotype, Biotechnology, Forward-looking statement, Research, Clinical trial, Pfizer, Travel, Corporation, CFO, NASDAQ, Acquisition, Neuroscience, Neoplasm, DMAC, Therapy, Department of Finance and Administration, Regulation, Management, Pharmaceutical industry, Oncolytics Biotech, Trillium, Finance

SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM.

Key Points: 
  • For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at www.sedar.com .
  • Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
  • Mr. Parsons is a life sciences industry veteran with over two decades of executive experience.
  • Prior to his time at Trillium, Mr. Parsons provided financial consulting services as the President of Empar Management.

Trillion Technology Solutions, Inc. awarded DoD JAIC Artificial Intelligence T&E BPA

Retrieved on: 
Friday, February 11, 2022
USCIS, CBP, Technology, RET, AI, JAIC, Government, Federal government of the United States, Research, SVC, Feedback, GSA, DEV, Scaled agile framework, Business, USMC, Solution, Psychiatry Innovation Lab, ICE, United States Department of Defense, Business development, DISA, ISO, ISO 9001:2015, DHS, SBA, FAA, FEMA, BPA, Joint Artificial Intelligence Center, Artificial intelligence, T&E, Air force, Deep learning, Partnership, DOJ, TRIL, NOAA, DOC, Multimedia, INC, Small Business Administration, COTS, Scrum, Cloud computing, Medical device, Kanban, Scrumban

RESTON, Va., Feb. 11, 2022 /PRNewswire/ --Trillion Technology Solutions, Inc. (TRILLION) is proud to announce that Trillion ERP VentureTech LLC, our JV with ERP International managed by TRILLION, has been awarded a spot on DoD's Joint Artificial Intelligence Center (JAIC) Artificial Intelligence Test & Evaluation (AI T&E) Blanket Purchase Agreement (BPA).

Key Points: 
  • RESTON, Va., Feb. 11, 2022 /PRNewswire/ --Trillion Technology Solutions, Inc. (TRILLION) is proud to announce that Trillion ERP VentureTech LLC, our JV with ERP International managed by TRILLION, has been awarded a spot on DoD's Joint Artificial Intelligence Center (JAIC) Artificial Intelligence Test & Evaluation (AI T&E) Blanket Purchase Agreement (BPA).
  • This five-year BPA allows TRILLION to provide Artificial Intelligence (AI) T&E services to JAIC, DoD, and the entire US Government.
  • ), says, "the JAIC T&E BPA provides us one more avenue to grow our partnership with DoD and continue to enhance our services to support the Warfighter."
  • Trillion Technology Solutions, Inc.provides innovative IT business solutions and services in the government and commercial sectors.

Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director

Retrieved on: 
Monday, December 20, 2021
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, Therapy, Deafness, Director, University of Chicago Booth School of Business, Company, Trillium, Board, Seagen, Diagnosis, Business, Sale, Biomarker, TRIL, CASC, Acquisition, NASDAQ, PFE, Bachelor, Usher syndrome, Independent Board for Presbyterian Foreign Missions, CEO, Patient, AMAG Pharmaceuticals, Leadership, Mutation, Hearing loss, University, AMAG, GJB2, Pharmaceutical industry, Management, Dentistry, Northwestern University, Pfizer, Biology

He was also an Independent Director at Trillium Therapeutics (TRIL) until its acquisition by Pfizer (PFE) in September of 2021.

Key Points: 
  • He was also an Independent Director at Trillium Therapeutics (TRIL) until its acquisition by Pfizer (PFE) in September of 2021.
  • In addition to his role at Dynavax and Harpoon, he is currently an Independent Board Director at Selecta Biosciences (SELB).
  • Nawal Ouzren, CEO of Sensorion, commented: We are delighted to welcome Scott as our new Chairman.
  • Scott Myers added: I am thrilled to be taking on the role of Chairman at this exciting phase of Sensorions development.

Trillium Therapeutics Receives Final Court Order Approving Arrangement

Retrieved on: 
Thursday, October 28, 2021
Argentum, CD47, Law of the United Kingdom, Cancer, US, EDGAR, TRIL, Failure, PFE, Pfizer, Arrangement, NASDAQ, SEDAR, NYSE, Toronto Stock Exchange, Risk, Annual report, Forward-looking statement, Disclosure, Supreme court, U.S. Securities and Exchange Commission, Immune system, GLOBE, Black–Scholes model, Pharmaceutical industry, Security (finance)

(Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the Arrangement) with PF Argentum ULC (PF Argentum), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (Pfizer).

Key Points: 
  • (Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the Arrangement) with PF Argentum ULC (PF Argentum), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (Pfizer).
  • The Arrangement is subject to regulatory approvals and clearances, as well as other customary closing conditions.
  • Following closing of the Arrangement, Trilliums Common Shares will be delisted from the Toronto Stock Exchange and NASDAQ.
  • Certain statements in this report may constitute forward-looking statements, which reflect the expectations of Trilliums management regarding the business prospects and opportunities of Trillium and the Arrangement.

Frazier Healthcare Partners Announces Several Promotions on Life Sciences Team

Retrieved on: 
Thursday, October 28, 2021
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Frazier Healthcare Partners, Sanofi Pasteur, Science, RNA transfection, ISEE, Biology, FLAC, Life, Eli Lilly, Initial public offering, O'Hara, U.S. Treasury, Treasury, General partnership, TRIL, Mergers and acquisitions, Public relations, NASDAQ, Machine learning, Capital market, List of life sciences, Equity capital markets, Roche, KRYS, Amgen, Senior advisor, General Atlantic, Morgan Stanley, Flagship Pioneering, Mergers & Acquisitions, Marketing, Investment, J. P. Morgan, Cancer, Growth, Safety, Acquisition, Intellectual property, Sanofi–Translate Bio COVID-19 vaccine, Biophysics, Fine chemical, Financial services

Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Fraziers public equity investment strategy.

Key Points: 
  • Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Fraziers public equity investment strategy.
  • Mr. Topper originally joined the Frazier Life Sciences team as a Senior Advisor in 2020 and currently serves as Chief Financial Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC).
  • Mr. Cabral joined the Frazier Life Sciences team in 2021 and focuses on identifying, evaluating, and creating new ventures.
  • It is very gratifying to see our team expand its capabilities, stated Patrick Heron, Managing Partner on Fraziers Life Sciences team.

Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund

Retrieved on: 
Thursday, October 28, 2021
Professional Services, Health, Finance, General Health, Pharmaceutical, Biotechnology, Frazier Healthcare Partners, Eli Lilly and Company, Eli Lilly, Initial public offering, General partnership, TRIL, NASDAQ, Roche, Growth, Acquisition, Sanofi–Translate Bio COVID-19 vaccine, Pharmaceutical industry, Fine chemical

Frazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise.

Key Points: 
  • Frazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise.
  • Led by Managing Partner Albert Cha, General Partner and Portfolio Manager Jamie Brush, and Managing Partners Patrick Heron and James Topper, Frazier Life Sciences Public Fund is a long-only fund investing in small- and mid-cap public biotech companies.
  • Frazier Life Sciences Public Fund marks Fraziers first dedicated public life sciences fund, bringing the firms total committed capital raised since inception to over $7.1 billion.
  • We are thrilled to announce the launch of our public life sciences fund, stated Albert Cha, managing partner on the Frazier Life Sciences team.

Trillium Securityholders Approve Acquisition by Pfizer

Retrieved on: 
Tuesday, October 26, 2021
Argentum, CD47, Cancer, US, TRIL, Failure, PFE, Pfizer, NYSE, Risk, Annual report, Forward-looking statement, Disclosure, U.S. Securities and Exchange Commission, Immune system, Proxy, GLOBE, Black–Scholes model, Security (finance)

(Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (PF Argentum) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (Pfizer) at the special meeting of Trillium securityholders today.

Key Points: 
  • (Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (PF Argentum) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (Pfizer) at the special meeting of Trillium securityholders today.
  • Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates.
  • Trillium is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
  • Certain statements in this report may constitute forward-looking statements, which reflect the expectations of Trilliums management regarding the business prospects and opportunities of Trillium and the arrangement.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Thursday, September 23, 2021
First Interstate BancSystem, Sun Capital Partners, KDMN, Pfizer, Sale, NASDAQ, GWB, Great Western, Fraud, TRIL, First Interstate, Advertising, NYSE, GLOBE, Security (finance)

If you are a Great Western shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Great Western shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.